JAIDS Journal of Acquired Immune Deficiency Syndromes
33:658–662 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 33, 2003

Author Index

Abad M, 253
Abbasi F, 34
Abbey NW, 308
Abraham OC, 219
Accolla RS, 47
Acosta EP, 343
Adult/Adolescent Spectrum of HIV Disease Project, 267
Agate LL, S238
Agins B, 484
Akincigil A, S76
Albini A, 47
Alcantara Jr LC, 536
Alcoba M, 253
Al-Harthi L, 175
Almond L, 551
Alston B, 329
Anastos K, 66
Andersen RM, 157
Andia I, 411
Andreoletti L, 121
Angarano G, 439
Anil CK, 407
Anthony KB, 125
Arendt V, 134
Ariyoshi K, 336
Auerbach JD, S57
Azzari C, 601

Bacchetti P, 66
Back D, 551
Baldwin C, 22
Balfour HH Jr, 343
Bansal A, 426
Barthélémy C, 461
Bassett R, 329
Batterham M, 543
Baurith T, 134
Beatty G, 34
Beaulieu ME, 470
Bélec L, 121
Berggren R, 329
Bernasconi E, 494
Bertz R, 650
Besch CL, 642
Bethel J, 585
Betts BJ, 8
Beyrer C, 259
Bhattacharya PDSK, 407
Bhatti L, 651
Biraro S, 411
Bisset LR, 292
Bittencourt AL, 536
Blaine J, 82
Blanchard S, 153
Blattner WA, 175
Boeri E, 146
Boerma T, 393
Böni J, 292
Bonora S, 439
Booth RE, S131
Borderi M, 405
Bottaro E, 279
Boulmé R, 134
Bowonwatanuwong C, 118
Boyd F, 506
Bozzette SA, 157
Bozzette SA, S76, S84
Braun J, 1
Brieschke MTR, 279
Briggs J, S84
Brobst S, 329
Brown D, 121
Brun-Vézinet F, 8
Buchacz K, 56
Bucher HC, 494
Buffa A, 405
Burnam MA, 104
Burning WJ, 329
Burtcel B, 506
Busch MP, 349, 655
Buvé A, 526
Byers RH, 625

Cagle HH, 199
Cahn P, 41
Callahan MM, 476
Calza L, 112, 408, 546
Campusano G, S106
Caraël M, 526
Cargnel A, 439
Carosi G, 439
Carpenter CCJ, 614
Carr A, 571
Carro JA, 253
CASCADE Collaboration, 184
Casssetti LI, 41
Catania JA, S115
Caudarella R, 405
Caudill SP, 625
Celentano DD, 259, 500
Celum CL, 476
Chadapaud S, 544
Chaikummao S, 194
Chaisson RE, 321, 577
Chakraborty B, 448
Chambers DB, S185
Chan D, 543
Chan KS, 104
Chandler B, 551
Chang S-C, 413
Chantratita W, 118
Chaowanachan T, 194
Charurat M, 175
Chen M-Y, 413
Chen S, 96
Chen SY, 166
Chen Z, 649
Chêne G, 380
Cheng A, 15
Chesney MA, S185
Chetchotisakd P, 118
Chiappini E, 601
Chiodo F, 112, 405, 408, 546
Choopanya K, 88
Chow D, 329
Chu J, 34
Chu PL, 191
Chung S-E, 247
Clarke-Tasker V, S106
CNAA2004 Study Investigators, 557
Cocaine Psychotherapy Study Group, 82
Cocchi D, 112
Coel M, 329
Cohen C, S29
Cohen DA, 642
Cohen M, 66
Colebunders RL, 448
Coletti AS, 476
Collins RL, 157
Colquhoun D, 329
Concha M, S93
Conigliaro J, 521
Connick E, 448

JAIDS Journal of Acquired Immune Deficiency Syndromes
33:658–662 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 33, 2003

Author Index

Abad M, 253
Abbasi F, 34
Abbey NW, 308
Abraham OC, 219
Accolla RS, 47
Acosta EP, 343
Adult/Adolescent Spectrum of HIV Disease Project, 267
Agate LL, S238
Agins B, 484
Akincigil A, S76
Albini A, 47
Alcantara Jr LC, 536
Alcoba M, 253
Al-Harthi L, 175
Almond L, 551
Alston B, 329
Anastos K, 66
Andersen RM, 157
Andia I, 411
Andreoletti L, 121
Angarano G, 439
Anil CK, 407
Anthony KB, 125
Arendt V, 134
Ariyoshi K, 336
Auerbach JD, S57
Azzari C, 601

Bacchetti P, 66
Back D, 551
Baldwin C, 22
Balfour HH Jr, 343
Bansal A, 426
Barthélémy C, 461
Bassett R, 329
Batterham M, 543
Baurith T, 134
Beatty G, 34
Beaulieu ME, 470
Bélec L, 121
Berggren R, 329
Bernasconi E, 494
Bertz R, 650
Besch CL, 642
Bethel J, 585
Betts BJ, 8
Beyrer C, 259
Bhattacharya PDSK, 407
Bhatti L, 651
Biraro S, 411
Bisset LR, 292
Bittencourt AL, 536
Blaine J, 82
Blanchard S, 153
Blattner WA, 175
Boeri E, 146
Boerma T, 393
Böni J, 292
Bonora S, 439
Booth RE, S131
Borderi M, 405
Bottaro E, 279
Boulmé R, 134
Bowonwatanuwong C, 118
Boyd F, 506
Bozzette SA, 157
Bozzette SA, S76, S84
Braun J, 1
Brieschke MTR, 279
Briggs J, S84
Brobst S, 329
Brown D, 121
Brun-Vézinet F, 8
Buchacz K, 56
Bucher HC, 494
Buffa A, 405
Burnam MA, 104
Burning WJ, 329
Burtcel B, 506
Busch MP, 349, 655
Buvé A, 526
Byers RH, 625

Cagle HH, 199
Cahn P, 41
Callahan MM, 476
Calza L, 112, 408, 546
Campusano G, S106
Caraël M, 526
Cargnel A, 439
Carosi G, 439
Carpenter CCJ, 614
Carr A, 571
Carro JA, 253
CASCADE Collaboration, 184
Casssetti LI, 41
Catania JA, S115
Caudarella R, 405
Caudill SP, 625
Celentano DD, 259, 500
Celum CL, 476
Chadapaud S, 544
Chaikummao S, 194
Chaisson RE, 321, 577
Chakraborty B, 448
Chambers DB, S185
Chan D, 543
Chan KS, 104
Chandler B, 551
Chang S-C, 413
Chantratita W, 118
Chaowanachan T, 194
Charurat M, 175
Chen M-Y, 413
Chen S, 96
Chen SY, 166
Chen Z, 649
Chêne G, 380
Cheng A, 15
Chesney MA, S185
Chetchotisakd P, 118
Chiappini E, 601
Chiodo F, 112, 405, 408, 546
Choopanya K, 88
Chow D, 329
Chu J, 34
Chu PL, 191
Chung S-E, 247
Clarke-Tasker V, S106
CNAA2004 Study Investigators, 557
Cocaine Psychotherapy Study Group, 82
Cocchi D, 112
Coel M, 329
Cohen C, S29
Cohen DA, 642
Cohen M, 66
Colebunders RL, 448
Coletti AS, 476
Collins RL, 157
Colquhoun D, 329
Concha M, S93
Conigliaro J, 521
Connick E, 448

Coon DW, S194
Costa MCR, 536
Covas DT, 536
Crits-Christoph P, 82
Crystal S, S59, S76
Cuevas MJ, 253
Culnane M, 153
Cunningham CK, 153
Currier JS, 506

d'Almada PJ, 232
d'Arminio Monforte A, 277
Dabis F, 380
Daftary M, S106
Damond F, 1
Darcourt J, 653
Darrow WW, 223
Dato A, 279
Davaro R, 279
De Bona A, 146
de Martino M, 601
Degula A, 349
Delaporte E, 239
Deroo S, 134
DerSimonian R, 125
Des Jarlais DC, 88
Descamps D, 8
Deschamps MM, 470
Dezii CM, 506
Disch WB, S138
Divi RL, 175
Djimasngar A, 239
Doherty SM, 281
Dolcini MM, S115
Dollard SC, 206
Domingo P, 114
Dominguez KL, 232
Dorenbaum A, 153
Dourado I, 536
Downing RG, 206
Dupon M, 380
Dworkin MS, 267

Edwards BH, 426
Eisdorfer C, S93, S171
Elbaggari A, 308
Elekwachi O, S106
Erbelding EJ, 247
Eskild A, 373
Esteban A, 594
European Collaborative Study, 635

Falloon J, 125
Farley J, 211
Farley TA, 642
Farthing CF, 651
Farzedegan H, 614
Feldman JG, 66
Fenaughty AM, 199
Fernandez MI, 608
Ferrando SJ, 116
Ferrini S, 47
Ferrus S, 211
Fichtenbaum CJ, 564
Filho AA, 536
Finkelstein R, 484
Fischer A, 134
Fischer M, 292
Fisher DG, 199
Fitzgerald DW, 470
Fleishman JA, S76
Flepp M, 494
Florence E, 448
Fogg C, 411
Ford J, 551
Foulke JS, 300
Fowler JP, S166, S243
Fowler MG, 232, 585
Frank A, 82
Fransen K, 448
Frederick T, 232
French T, 484
Frezieres RG, 476
Friis H, 74
Frye V, 548
Furrer H, 494

Gai F, 476
Galli L, 146, 601
Galli M, 277
Gallop R, 82
Gallotta G, 146
Galvão-Castro B, 536
Gange SJ, 66
Gastfriend D, 82
Gatti N, 277
Gazzard BG, 22
Gelber RD, 153
George R, 219
Gibson A, 300
Gibson S, 166, 191
Gifford AL, 104, 157
Gigliotti M, 41
Gisselquist D, 119
Glesby MJ, 329
Glynn JR, 526
Goepfert PA, 426
Goldwasser P, 66
Gomo E, 74
Gonçalves MS, 536
Gonzalez D, 134
Goodkin K, S93, S171
Gordon AJ, 521
Gough E, 426
Graeme JMoyle S7
GrandPierre R, 470
Grant RM, 655
Green C, 308
Grésenguet G, 121
Gringeri A, 47
Gripshover B, 605
Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA), 380
Gueudin M, 1
Gui X, 649
Günthard HF, 292
Gutiérrez F, 594

Hall DB, 41
Halpern SD, 412
Hanchard B, 387
Hannon WH, 625
Harris DR, 585
Hays RD, S76
Hecht FM, 349
Heckman T, S171
Hemmer R, 134
Henne J, 191
Hernández I, 594
Herndier B, 308
Herrmann SE, 29
Hines S, 211
Hiranrus K, 88
Hirschel B, 494
Hisada M, 387
Hittinger G, 544
Hladik W, 206
Hodder S, 506
Hogan JW, 500, 614
Hoggard P, 551
Holmes D, S206
Holtgrave DR, 171
Hsiao A-F, 157
Hsieh S-M, 413
Hsu H-W, 232
Hsu L, 96
Hughes MD, 56
Hui DY, 564
Hung C-C, 413

Ickovics J, 608
Intile AD, 279
Irwin KL, 247
Isaacson E, 15
Isingo R, 393

Jacobson LP, 140
Jacqmin-Gadda H, 380
James IR, 29
Janssen RS, 349, 625
Jeganathan S, 543
Jesudason MV, 219
Jimenez AD, S222
Jin X, 308
Jittiwutikarn J, 259
John M, 29
Johnson LM, S185
Johnson WA, S229
Johnson WD Jr, 470
Jolly P, 544
Joseph P, 470
Joyce G, 104
Justice AC, 521, S84

Kabelitz D, 420
Kahindo M, 526
Kamb ML, 247
Kandula VR, 651
Kannangai R, 219
Kanouse DE, 157, 276
Kapp L, 308
Karon JM, 206
Kashima S, 536
Kaslow RA, 140, 426
Kataaha P, 206
Katz M, 96
Katz MH, 274
Kawabata H, 506
Kawichai S, 259
Kelleher D, 557
Kelly CW, 476
Kennedy M, S122
Khalili M, 34
Khamis I, S93, S171
Khanlou H, 651
Khoo S, 551
Kilbourne AM, S84
Kilmarx PH, 194
Kitayaporn D, 88
Klein MB, 365
Klein RS, 356, 614
Klein SJ, S243
Knodel J, S153
Ko H, 500
Koch J, 34
Koenig L, 608
Koester KA, 513
Korber B, 426
Korkontzelou C, 614
Kothe D, 625
Koyalta D, 239
Krarup H, 74
Kropp J, 655
Kuritzkes DR, 448
Kwiatkowski CF, S131

Lackritz EM, 206
Lafeuillade A, 544
Lalonde RG, 365
Lambert C, 134
Lambert J, 585
Lambry V, 544
Landay A, 448
Landay AL, 175
Lane HC, 125
Langroudi B, 22
Law M, 571
Lazzarin A, 146
Le Buanec H, 47
Lebedeva L, 349
LeBlanc S, 140
Lechiche C, 239
Lecusay R, S93, S171
Ledergerber B, 292
Lederman MM, 448, 557
Lee D, S93, S171
Lee T-H, 655
Legoff J, 121
Legros D, 411
Leibowitch J, 461
Leste-Lasserre T, 461
Levine PH, 387
Levy JA, S59, S138, S206
Liautaud B, 470
Liberti TM, S238
Limpakarnjanarat K, 194
Lindegren ML, 232
Lindsey JC, 56
Linsk N, S171
Linsk NL, S243
Lipman DJ, S194
Liu A, 194
Liu H, 157
Liu Y, 308
Lo Y, 356
Lobozzo J, 548
Losso M, 41
Luborsky L, 82
Lucas GM, 321

Maa J-F, 506
Macalino GE, 500
Mack KA, S68
Mack KD, 308
Madsen PH, 74
Maiorana A, 513
Maldonado M, 653
Malkin J-E, 121
Mallal SA, 29
Mandalia S, 22
Manfredi R, 112, 408, 546
Marchetti G, 277
Margolick JB, 614
Margot NA, 15
Maroldo-Connelly L, 650
Marotta ML, 448
Marston M, 393
Martin V, 253
Martin-Hidalgo A, 594
Masiá M, 594
Mason SJ, S171
Mastro TD, 88
Mathez D, 461
Mathieson B, 585
Matsuda M, 336
Matta M, 121
Mauck CK, 476
Mauclère P, 1
Mayanja B, 411
Mayaud P, 121
Mayer KH, 614
Mazza S, 47
Mbopi-Kéou F-X, 121
McComsey G, 605
McCutchan A, 157
McDonough M, 41
McFarland W, 96, 166, 191
McGinnis KA, 521
McGowan I, 15
McGrath MS, 308
McKinnon EJ, 29
McMahon D, 557
Meazza R, 47
Mehta SH, 577
Mei JV, 625
Mella I, 373
Mellors J, 557
Melville SK, 232
Menon V, 653
Mercié P, 380
Merges M, 300
Merigan TC Jr, 329
Mermin J, 206
Meroni L, 277
Metcalf JA, 125
Meyer WA III, 585
Michaelsen KF, 74
Michelmore H, 543
Miller M, 373
Miller MD, 15
Miller P, 191
Mirochnick M, 153
Miura H, 336
Mock PA, 88
Moench TR, 476
Mofenson L, 153, 585
Moi H, 373
Monno L, 439
Montaner JSG, 41
Montoya ID, S218
Moore CB, 29
Moore RD, 321, 577
Mootsikapun P, 118
Morin SF, 513
Morlat P, 380
Morsica G, 146
Mostaza J-L, 253
Moyle GJ, 22, S17
Muça-Perja M, 47
Mulligan MJ, 426
Mullins JM, S238
Murphy EL, 655
Murphy RL, S43
Musk A, 211
Musonda RM, 526
Mwaluko G, 393

Naik E, 140
Navarro A, 594
Naviaux RK, 461
Ndhlovu P, 74
Ndinaromtan T, 239
Neau D, 380
Nemo G, 585
Netski D, 356
Ng'weshemi J, 393
Ngalula J, 393
Nguyen V, 175
Noel F, 470
Nolan DA, 29

Noonan DM, 47
Nyazema N, 74

Oleske JM, 56
Oliveira A, 655
Olivero OA, 175
Ong O, 653
Opravil M, 292
Ordoñez J, 114
Orenstein JM, 125
Orlando M, 104
Ortega L, 253
Ortiz de Urbina J, 253
Ortiz IR, 232
Ory MG, S59, S68, S194
Owen A, 551

Padilla S, 594
Pal R, 300
Pan S-C, 413
Pape JW, 470
Partridge T, 191
Pastore G, 439
Patterson JB, 650
Paugam A, 411
Paul JP, 223
Peck R, 470
Peeters M, 239
Pellett PE, 206
Pepper L, 411
Pérez A, 114
Perez-Simon M-R, 253
Perkins C, 426
Peters VB, 232
Petit C, 461
Philip G, 544
Pinkerton SD, 171
Plantier J-C, 1
Poindexter AN III, 476
Poindexter CC, S171
Poirier MC, 175
Polis MA, 125
Pollack L, S115
Potterat JJ, 119
Powderly WG, S5, S7
Powell NJ, S106
Praschunus R, 300
Prasithiphol B, 88
Priotto G, 411
Priya A, 407
Profy AT, 476
Prudent ES, S238

Quiñones-Mateu ME, 448

Rabeneck L, 521, S84
Rabkin J, 116
Rakusan TA, 232
Ramalingam S, 219
Ramaroson H, 380
Ramos J, 594
Rangel HR, 448
Ranjan A, 407
Rapaport S, 650
Ravela J, 8
Rawal BD, 349
Raya C, 253
Razak MHtoo, 259
Reaven GM, 34
Reichman RC, 329
Reid C, 8
Reitz M, 300
Rich JD, 500
Richard V, 239
Richards TA, 513
Richardson BA, 476
Rickenbach M, 494
Ricuarte J-C, 651
Riddle TM, 564
Ritter GD, 426
Roark RA, 223
Robinson PA, 41
Rodriguez-Barradas M, S84
Rogers AS, 56
Rogol AD, 56
Roman F, 134
Rompalo AM, 247
Rosen A, 34
Rosso O, 47
Ruan P, 557
Rungruengthanakit K, 259
Ryan ER, 116

Sabbaj S, 426
Sadek R, 232
Sajja P, 653
Salamon R, 380
Salata R, 605
Salloum IM, 82
Sambamoorthi U, S76
Sambeat MA, 114
Sanchez S, 651
Sangkhum U, 88
Santos FLN, 536
Saracino A, 439
Satten GA, 625
Sawada T, 387
Sawanpanyalert P, 259
Scapellato JL, 279
Scapellato PG, 279
Schapiro JM, 8
Schensul JJ, S138
Schmidt JM, 34
Schmit J-C, 134
Schneider F, 134
Schoenbaum EE, 500
Schuman P, 500, 614
Schüpbach J, 292
Schwarcz S, 96, 191
Schwartz DH, 219
Scudeller L, 439
Seage GR III, 56
Sereti I, 125
Severe P, 470
Shafer RW, 8
Shaji RV, 219
Shanmugam AP, 219
Shapiro MF, 157, S76
Sharp V, 548
Sheon NM, 513
Sheppard HW, 349
Sherbourne CD, 104
Sherman KE, 329
Shiramizu B, 329
Siddique NA, 407
Siegel K, S171
Si-Mohamed A, 121
Simon F, 1
Sinha PK, 407
Sinicropi G, 405
Smith CA, 116
Smith D, 614
Smith K, 8
Smith KY, 448
Smith M, S206
Smola S, S84
Sonigo P, 461
Soto-Torres LE, 476
Southwell H, 605
Squires KE, 66
Sridharan G, 219
Srirak N, 259
Stall RD, S115
Stansell J, 34
Staub T, 134
Stein TG, 651
Stempel RR, 223
Sterk CE, S229
Stevens RA, 125
Stevens RC, 650
Stiehm ER, 585
Strasfeld L, 356
Strombeck R, S226
Study Group on the Heterogeneity of HIV Epidemics in African Cities, 526
1100.1286 Study Team, 41
Su B, 649
Suarez P, S93, S171
Sugiura W, 336
Suissa S, 365
Sulkowski MS, 577
Sullivan JL, 153
Sungkanuparph S, 118
Supawitkul S, 194
Suriyanon V, 259
Suss A, 608
Swiss HIV Cohort Study, 292, 494
Symes S, S93
Szinger JJ, 426

Tabet SR, 476
Tampellini L, 405
Tang J, 140, 426
Tansuphaswaswadikul S, 118
Tappero JW, 88
Tassie J-M, 411

Tateishi S, 336
Taub D, S84
Taylor A, 506
Taylor B, 300
Taylor JM, S185
Telenti A, 494
Tepper V, 211
Tesoriero J, 484
Theodore D, 329
Thiébaut R, 380
Thomas DL, 356, 577
Thomas J, 281
Tien P, 649
Tomasik Z, 292
Tovanabutra S, 259
Truax J, S169
Tucker JS, 104

Uberti-Foppa C, 146
Urassa M, 393

Valdez H, 448, 605
van Damme L, 476
Van Dooren S, 536
van Gorp WG, 116
van Griensven F, 88
Van Laethem K, 8
van Zuilen MH, S93
Vandamme A-M, 8, 536
Vanham G, 448
Vanichseni S, 88
VanLandingham M, S153
VanVeldhuisen PC, 387
Verdier RI, 470
Vernazza P, 494
Verucchi G, 546
Vescini F, 405
Vibhagool A, 118
Vidal GI, 279
Vidal N, 239
Visnegarwala F, 653
Vlahov D, 614
Vongchak T, 259

Wagner GJ, 276
Wagner J, S84
Walker B, 175
Walker VE, 175
Walsh TL, 476
Walter E, 608
Walters M, 387
Waters M, 484
Watkins S, S153
Watts DH, 585
Weber J, 448
Weber R, 494
Webster RD, 223
Wei R, 308
Weide D, 166, 191
Weiss H, 121
Weiss L, 484
Weissman S, S84
Wells RS, 199
Wenger N, S76
Wenger NS, 157, S84
Wesch D, 420
White AC Jr, 653
White AJ, 29
Whitsett DD, S218
Wilkie FL, S93
Wilks R, 387
Williams C, 66
Williamson JM, 267
Wilson CM, 56, 426
Wilson TE, 608
Winslow DL, 8
Wolf K, 494
Wolfe R, 548
Wong MD, 157
Woods WJ, 223
Woodward R, 300
Woody GE, 82
Wright ER, S233
Wright P, 470
Wruck J, 41
Wu H, 557
Wu S-Y, 642
Wutoh AK, S106

Yamada K, 336
Yanpaisarn S, 194
Yeh V, 651
Yoder C, 125
Young J, 494
Young M, 66
Yu S, 308

Zaba B, 393
Zablotsky D, S122
Zala C, 41
Zhang L, 649
Zhuang K, 649
Zingmond DS, S76, S84

JAIDS Journal of Acquired Immune Deficiency Syndromes
33:663–672 © 2003 Lippincott Williams & Wilkins, Inc., Philadelphia

Journal of Acquired Immune Deficiency Syndromes
Volume 33, 2003

Subject Index

α_1-Antichymotrypsin, iron, haptoglobin phenotype, and HIV-1 viral load: study among pregnant women, 74
Abacavir
  and combivir, switching with stavudine and/or protease inhibitors to for prevention or reversal of lipoatrophy, 29
  replacement in managing dyslipidemia and peripheral lipoatrophy, 22
Acceptability
  and performance of rapid HIV testing among northern Thailand women, 194
  and safety of penile application of topical microbicides, 476
Acquired immunodeficiency syndrome, economic implications of failure to reduce, by 50% by 2005 in U.S., 171
Adherence
  antiretroviral, in older HIV-infected patients, assessment and predictors, S106
  to antiviral therapy, children with HIV using MEMS, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping, 211
  to HAART in treatment adherence demonstration project, 484
  interventions for highly active antiretroviral therapy, assessing usual care in clinical trials of (letter), 276
  to triple antiretroviral treatment including indinavir, role of determination of plasma levels of indinavir, 253
Adolescents
  delayed onset of pubertal development in children and, with perinatally acquired HIV infection, 56
  and HIV prevalence and risks among injection and noninjection drug users in northern Thailand, 259
Adrenarche, and puberty, delayed in children and adolescents with perinatally acquired HIV infection, 56
Africa
  HIV risk and marriage in areas with high prevalence of HIV infection, 526
  Kaposi's sarcoma in Uganda, 206
Aging
  American drug users and HIV risk behaviors, S131
  among diverse HIV-positive population: national profile of economic circumstances, social support, and quality of life, S76
  with HIV: one woman's story, S166
  HIV/AIDS prevention and care services for, S243
  HIV-1-infected adults, cognitive functioning, S93
  and HIV infection/AIDS, S171
  late-onset crack users: emergent HIV risk group, S229
Aging and AIDS, research on conceptual and methodological issues for, S206
AIDS
  combination antiretroviral therapy and improvements in mental health: results in US, 104
  differences in symptom expression in older patients, S84
  impact of tuberculosis on in persons with well-documented time of HIV seroconversion, 184
  incomplete CD4 T cell recovery in, after HAART associated with CD4 T cell activation and turnover, 125
  and older Americans at end of twentieth century, S68
  persons with, low socioeconomic status associated with higher death rate in HAART San Francisco and, 96
  prevention activities among seniors in south Florida, S238
  putting a face on HIV infection and, in older adults, S171
  social support, distress, and well-being in older men living with, S185
  wasting syndrome: trends, influence on opportunistic infections, and survival, 267
AIDS and older adults, interventions, S59
AIDS dementia, HIV integration within host cell genomic DNA and macrophage-associated p24 antigen expression, 308
AIDS lymphoma, HIV integration within host cell genomic DNA and macrophage-associated p24 antigen expression, 308
AIDS prevention in older population, interventions, S59
Alcohol, hazards of use and abuse in HIV infection, 521
Amyl nitrate, and Viagra use in community-recruited sample of MSM, San Francisco, 191
Antibody titer, seroincidence of HTLV-1 infection and characterization of seroconverters in Jamaican food handlers, 387
Antihepatitis C virus therapy, pretreatment of chronic active hepatitis C with HIV and hepatitis C virus reduces hepatotoxicity in, 146
Antioxidants, effects on glucose metabolism and plasma lipids in HIV-infected subjects with lipoatrophy, 605
Antiretroviral drug
  point mutations linked with, treatment failure in CRF01_AE (subtype E) differ from subtype B, 336
Antiretroviral therapy(-ies)
  blood lymphocyte mitochondrial DNA for monitoring antiretroviral drug-induced mitochondrial DNA depletion, 461
  chronic HCV in HIV patients with hepatitis C virus reduces hepatotoxicity associated with, 146

clinical and immunologic progression in HIV-infected US women before and after introduction of, 614
HIV infection and risk of osteoporosis (review article), 281
HIV-1 p24 antigen as inverse correlate of CD4 T-cell change in patients under, 292
impact of HCV coinfection on HIV progression before and after, 365
and improvements in mental health: results in US, 104
survival in HIV-1 clinic in era of, 321
Antiretroviral treatment, and advanced age (letter), 112
Anti-tax, seroincidence of HTLV-1 infection and seroconverters in Jamaican food handlers, 387
Anxiety, putting a face on HIV infection/AIDS in older adults, S171
Assay correlation, risk factors for HHV-8 infection among blood donors linked to Kaposi's sarcoma in Uganda, 206
AUDIT, hazards of in HIV infection, 521

Bacterial, STDs, value of screening for, in HIV clinic, 642
Bangkok, Thailand, and HIV risk reduction in injecting drug users, 88
Bantu, globin haplotypes of HTLV-1-infected persons in Salvador, Bahia, Brazil, suggest post-Columbian African origin of virus, 536
β-globin haplotypes, of HTLV-1-infected individuals in Salvador, Bahia, Brazil, suggest post-Columbian African origin of virus, 536
Binge drinking, hazards in HIV infection, 521
Bisexual, older men and HIV epidemic, S115
Blood donors, HHV-8 infection among linked to Kaposi's sarcoma in Uganda, 206
Body composition, lipodystrophy severity grading scale derived from LDCD, 571
Bone mass in HIV-infected patients (letter), 405
Bone mineral density, HIV infection and risk of osteoporosis (review article), 281
BufferGel, safety and acceptability of penile application, 476

CCR5, -tropic HIV-1 Ba-L, simian human immunodeficiency virus encoding envelope gene from, 300
CD4 cell count
among HIV-infected patients with AIDS-defining disease (letter), 279
and cognitive functioning in younger and older HIV-1-infected adults, S93
hazards of alcohol use and abuse in HIV infection, 521
and survival in HIV-1 clinic in era of HAART: 5-year study, 321
CD8 T cell responses, identified in US adolescent minorities, 426
CD4 T lymphocytes, and HIV-1 p24 in patients under long-term antiretroviral therapy, 292
$CD4^+$ T lymphocytes, and HIV RNA in naive HIV-1-infected patients treated with HAART, 380
Cellular activation, incomplete CD4 T cell recovery in HIV-1 after HAART associated with, and turnover, 125
Cellular proliferation, and turnover, incomplete CD4 T cell recovery in HIV-1 after HAART associated with, 125
Cesarean section, in HIV-infected women in U.S. from 1994–2000, increasing trends of, 232
Challenges, methodological, in research on age and aging, S206
CHD incidence, in HIV-infected individuals, 506
Chemokine, characterization of SHIV from CCR5-tropic HIV-1 Ba-L, 300
Child mortality, HIV impact on mother and, in rural Tanzania, 393
Children
delayed onset of pubertal development in, and adolescents with perinatally acquired HIV infection, 56
with HIV-1, IL-7 and immunologic failure despite treatment with HAART in, 601
HIV-infected, using MEMS, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping, adherence to antiviral therapy in, 211
Chlamydia infection, value of screening for STDs in HIV clinic, 642
Clinical trial, of needle exchange and injection drug use frequency, 199
Cocaine dependence, HIV risk reduction in NIDA cocaine collaborative treatment study, 82
Cognition, in younger and older HIV-1-infected adults, S93
Cognitive dysfunction, screening subtle HIV-related (letter), 116
Combination therapy, low socioeconomic status associated with higher rate of death in San Francisco, in era of, 96
Combivir, and abacavir, switching with stavudine and/or protease inhibitors to, for preventing or reversing lipoatrophy, 29
Communicable disease control, prevalence of unsafe sexual behavior among HIV-infected individuals: cohort study, 494
Community advisory boards, community consultation in HIV prevention research: study, 513
Community consultation, in HIV prevention research: study of community advisory boards, 513
Community partnerships, in HIV prevention research, 513
Complementary and alternative medicine (CAM), and substitution for conventional therapy by HIV patients, 157
Compliance, assessment and predictors of antiretroviral adherence in older HIV-infected patients, S106
Condom use, risk factors and HIV transmission to mature women, S122
Contamination, of usual care control, assessing: rationale 3 (letter), 276
Contextual risk, factors affecting HIV/AIDS risk among older adults in low-income senior housing complexes, S138
Contraception, family planning and unprotected sex: among HIV-infected and uninfected postpartum US women, 608
Coronary heart disease, in HIV-infected individuals, 506
Cost and cost analysis, of failure to reduce incident HIV infections by 50% by 2005 in U.S., 171
Cost-benefit analysis, value of screening for STDs in HIV clinic, 642

CRF01_AE (subtype E), infection and subtype B, point mutations linked with antiretroviral drug treatment failure in, 336
Cross-site variations, in usual care and effectiveness, assessing: rationale 2 (letter), 276
Cryptococcal antigenemia, in HIV-positive adults in Uganda, systematic screening (letter), 411
CTL epitopes, identified in US adolescent minorities, 426
CTL vaccines, cross-reactive $CD8^+$ T cell epitopes identified in US adolescent minorities, 426
Cybersex, high-risk practice among older adults, S226

Delayed-type hypersensitivity skin testing, predicting CD4 count increase in HIV patients with poor immunologic response to HAART (letter), 277
Depression
  putting a face on HIV infection/AIDS in older adults, S171
  social support, and well-being in older men living with HIV infection, S185
Developing country, HIV voluntary counseling and testing as strategy for prevention of HIV transmission in, 470
Diagnosis, of lipodystrophy using LDCD, 571
Directly observed therapy, in highly nonadherent HIV-infected patients in urban community-based institution (letter), 651
Disclosure, of HIV serostatus to sexual partners among MSM, 157
Disease progression
  of HIV and impact of TB in persons with well-documented time of HIV seroconversion, 184
  of HIV in women after delivery, 585
DMB, HLA class II associated with disseminated *Myocobacterium avium* complex infection in HIV-1-seropositive whites, 140
DQBI, associations with disseminated *Myocobacterium avium* complex infection in HIV-1-seropositive whites, 140
DRBI, associations with disseminated *Myocobacterium avium* complex infection in HIV-1-seropositive whites, 140
Drug resistance
  administration of high-dose stavudine to nucleoside-experienced persons infected with HIV-1, 343
  genotypic, interpretation algorithms, HIV-1 protease and reverse transcriptase, 8
  patterns of point mutations linked with, in CRF01_AE (subtype E) differ from subtype B, 336
Drug toxicity, LPV plasma concentrations and changes in lipid levels during salvage therapy with LPV/r-containing regimens, 594
Drug use
  emergent HIV risk group, S229
  and HIV risk behaviors among older Americans, S131
Drug users, hepatitis C prevalence, activity, and genotype with HIV infection in cohort of New York City, 356
Dyslipidemia
  and lipoatrophy, managing with abacavir-based substitution, 22
  LPV plasma concentrations and changes in lipid levels during salvage therapy with LPV/r-containing regimens, 594

Early HIV infection
  new less-sensitive enzyme immunoassay for detection of, 349
  performance of new LS HIV-1 EIAs in estimating HIV seroincidence, 625
Efavirenz-based regimen, as treatment of AIDS with cryptococcal meningitis (letter), 118
Elderly, minority populations, new frontiers and challenges in HIV research among, S218
Electronic monitoring, of HIV-infected children using MEMS, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping, and adherence to antiviral therapy, 211
Enfuvirtide, mutations at residue positions critical for, resistance in patients with subtype B and non-B HIV-1, 134
Envelope nucleotide sequence, of HIV-2 subtype circulating in India (south), 219
Envelope protein, from CCR5-tropic HIV-1 Ba-L, simian human immunodeficiency virus encoding, 300
Enzyme immunoassay, performance of new LS HIV-1, for estimating HIV seroincidence, 625
Epidemiology
  of AIDS and older Americans at end of twentieth century, S68
  and HIV infection associated with risks among MSM in Florida resort community, 223
Epitopes mapping, in inactivated tat-vaccinated healthy and HIV-1-infected volunteers, 47
Ethnic minorities, and HIV prevalence and risks among injection and noninjection drug users in northern Thailand, 259
Europe, gender and race differences in cellular immunity patterns over age in infected and uninfected children of HIV-infected women, 635
Evaluation of antiretroviral potency, in treatment-naive HIV-1-infected patients receiving abacavir with HIV-1 PIs, 557

Family, AIDS and older persons, S153
Family planning, contraception, and unprotected sex: among HIV-infected and uninfected postpartum US women, 608
Ferritin, iron, haptoglobin phenotype, and HIV-1 viral load: cross-sectional study among pregnant women, 74
Florida, south, reaching seniors in retirement communities and social networks with HIV/AIDS prevention activities, S238
Flow cytometry, differential expression of natural killer receptors on Vδ1 γδ T cells in HIV-1-infected patients by, 420

Gay, older men and HIV epidemic, S115
γδ T lymphocytes, differential expression of natural killer receptors on, in HIV-1-infected patients, 420
Gender, and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women, 635
Genetic diversity, of HIV-1 strains Chad, West Central Africa, 239

Genetics, associated with disseminated *Myocobacterium avium* complex infection in HIV-1-seropositive whites, 140
Genotype
  HIV-1 phenotypic susceptibility to LPV and, in LPV/r-naive subjects with PI experience, 439
  HIV-1 resistance tests, algorithms developed for interpreting results, 8
  infection, patterns of point mutation linked with antiretroviral drug treatment failure in, 336
Geriatric, minority populations, HIV research among, S218
Glucose intolerance, quantification of in HIV-infected individuals: comparing PI-treated and non-PI-treated, 34
Gonorrhea, value of screening for STDs in HIV clinic, 642

Haplotype, complexity of associated with disseminated *Myocobacterium avium* complex infection in HIV-1-seropositive whites, 140
Haptoglobin phenotype, iron, and HIV-1 viral load: cross-sectional study among pregnant women, 74
HCV, prevalence, activity, and genotype with HIV in cohort in New York City drug users, 356
Health services needs and demand, in failure to reduce HIV infections by 50% by 2005 in U.S., 171
Hepatitis C virus
  coinfection on HIV progression before and after HAART, 365
  and HAART on development of hyperglycemia in HIV-infected persons, 577
  and HIV in injecting drug users in Oslo, Norway, 373
  prevalence, activity and genotype with HIV infection in cohort in New York City drug users, 356
  SPECT parameters as alternative to liver biopsies in assessing liver involvement in setting of HIV and, 329
Heroin, HIV and hepatitis C virus risk in injecting drug users in Oslo, Norway, 373
Herpes simplex virus-2
  as cofactor in HIV transmission (letter), 119
  genital shedding of and HSV-2-coinfected African women, 121
Heterosexual transmission, of HIV and marriage in areas with high prevalence of HIV infection, 526
Highly active antiretroviral therapy
  and AIDS wasting syndrome, 267
  assessment of adherence to, including indinavir, role of determination of plasma levels of indinavir, 253
  and HCV infection on hyperglycemia in HIV-infected persons, 577
  IL-7 and immunologic failure despite treatment with, in children with HIV-1 infection, 601
  and serum albumin as predictor of survival in HIV-1-infected women, 66
  stability of adherence to, in treatment adherence demonstration project, 484
  study of switching stavudine and/or PI to combivir/abacavir to prevent or reverse lipoatrophy in HIV patients, 29
  viral dynamics to baseline factors and virologic responses in treatment-naive HIV-1-infected patients receiving abacavir, 557
Hispanic, men and HIV infection with risks among MSM in Florida resort community, 223
HIV
  and aging: one woman's story, S166
  differences in symptom expression in older patients, S84
  first-line treatment in, S29
  and HCV, correlation of SPECT parameters as alternative to liver biopsies in assessing liver involvement in, 329
  and hepatitis C virus risk in injecting drug users in Oslo, Norway, 373
  impact on mother and child mortality in rural Tanzania, 393
  insertions within and proximal to host cell genes in tissues with high levels of HIV DNA and macrophage-associated p24 antigen expression, 308
  and older Americans at end of twentieth century, S68
  perinatally acquired, infection and delayed pubertal development in children and adolescents with, 56
  point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) differ from subtype B, 336
  progression among women after delivery, 585
  research among older minority populations, S218
  risk, travel, and tourism among older adults, S233
  risk behaviors among older American drug users, S131
  risk group, late-onset crack users, S229
  risk in relation to marriage in area of high prevalence of HIV infection, 526
  volunteers, immunodominant epitopes in inactivated tat-vaccinated healthy and, 47
HIV-1
  Ba-L, simian human immunodeficiency virus encoding envelope gene from CCR5-tropic, 300
  clinic in era of highly active antiretroviral therapy: 5-year study, 321
  effects of prednisone on rash with nevirapine in, 41
  infected children, adherence to antiviral therapy in, using MEMS, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping, 211
  infected patients, differential expression of natural killer receptors on Vδ1 γδ T cells in, 420
  seropositive whites, HLA class II associated with disseminated *Myocobacterium avium* complex infection in, 140
  viral load, iron, haptoglobin phenotype and: cross-sectional study among pregnant women, 74
HIV-2, subtype circulating in India (South), 219
HIV/AIDS
  and older persons: international perspective, S153
  and older population: national profile of economic circumstances, social support, and quality of life, S76
  prevention and care services for aging: bridging gap between service systems to assist older people, S243
HIV-AIDS, patients, assessment and predictors of antiretroviral adherence in, S106
HIV/AIDS and aging, interventions for, S59
HIV/AIDS knowledge, among midlife and older women, S122
HIV/AIDS prevention
  for mature men, S194
  risk factors among older residents in low-income senior housing complexes, S138

HIV/AIDS risk, among older lower-income residents in senior housing complexes, factors affecting, S138
HIV care, feasibility, demand and effect of, with voluntary counseling and testing, 470
HIV cost and services utilization study, and diverse older HIV-positive population, S76
HIV-1 diversity, and plasma RNA quantification, 1
HIV incidence
development of less-sensitive EIA for detection, 349
performance of new LS HIV-1 EIAs in, 625
HIV-infected immigrants, from non-European union countries and antiretroviral treatment (letter), 408
HIV-1 infection
IL-7 and immunologic failure despite treatment with HAART in children with, 601
in older adults: psychosocial context, S171
in younger and older, cognitive functioning, S93
HIV infection/AIDS, living with, and aging, S169
HIV infection(s)
among women and children in Henan Province, China (letter), 649
and coronary heart disease, 506
in patients treated with HAART and $CD4^+$ T lymphocyte count and, 380
prevalence of unsafe sexual behavior in individuals with, 494
prevention activities among seniors in south Florida, reaching retirement communities and aging social networks, S238
risk factor for osteoporosis (review article), 281
in US women before and after introduction of HAART, clinical and immunologic progression in, 614
HIV-l-infected patients, treatment with Tenofovir disoproxil fumarate in treating, 15
HIV-1 load, and hazards of alcohol use and abuse, 521
HIV-positive, older men, social support, distress, and well-being in, S185
HIV prevalence, among older men who have sex with men, S115
HIV-1 prevalence, and risks among injection and noninjection drug users in northern Thailand 259
HIV prevention, feasibility, demand, and effect of integrating primary care with voluntary counseling and testing, 470
HIV/prevention and control, in HIV clinic, 642
HIV Prevention Trials Network, community consultation in HIV prevention research, 513
HIV-1 protease, and reverse transcriptase mutation patterns between genotypic drug resistance interpretation algorithms, 8
HIV risk, reduction in National Institute on Drug Abuse Cocaine Collaborative Treatment Study, 82
HIV risk behaviors, among minority MSM, S222
HIV risk reduction, in injecting drug users in Thailand, 88
HIV-1 RNA
HIV-1 p24 antigen as inverse correlate of CD4 T-cell change in patients under long-term antiretroviral therapy, 292
HIV-1 RNA,
survival in HIV-1 clinic in era of HAART, 321
HIV-1 suppression, in treatment-naive patients undergoing 4- to 3-drug induction maintenance therapy (letter), 543
HIV testing
development of new less-sensitive enzyme immunoassay for, 349
performance of new LS HIV-1 EIAs in, 625
HIV therapies, limitations of current, S7
HIV transmission, new sexually transmitted diseases in HIV-infected patients, markers for, 247
HIV transmission and risks among MSM in Florida resort community, 223
HIV trends in serum albumin, and survival predictions among women, 66
HIV vaccine, cross-reactive $CD8^+$ T cell epitopes identified in US adolescent minorities, 426
HIV virus/therapy, value of screening for STDs in HIV clinic, 642
HLA-DMA, complexity of, associated with disseminated *Mycobacterium Avium* complex infection among HIV-1-seropositive whites, 140
Homosexual men, and HIV infection and associated risks among, in Florida resort community, 223
Human herpes virus 8, risk factors among blood donors linked to Kaposi's sarcoma in Uganda, 206
Human T-cell lymphotropic virus type 1
globin haplotypes of, in Salvador, Bahia, and Brazil 536
seroincidence of, infection and characterization of seroconverters in Jamaican good handlers, 387
Human T-lymphotropic virus type II, proviral load after HAART in HIV-coinfected patients, increased, 655
Humoral response, identification of epitopes in inactivated tat-vaccinated healthy and HIV-1-infected subjects, 47
Hyperglycemia, in HIV-infected persons, effect of HAART and HCV infection on development of, 577
Hyperlipidemia, LPV plasma concentrations and changes in lipid levels during salvage therapy with LPV/r-containing regimens, 594

IDU, in Oslo, Norway, HIV and hepatitis C virus in, 373
IL-7, and immunologic failure despite treatment with HAART in children with HIV-1 infection, 601
Immune reconstitution, HIV-1 p24 antigen as inverse correlate of, in patients under antiretroviral therapy, 292
Independent predictor of survival, serum albumin and HIV-1 infected women, 66
India (south), HIV-2 subtype circulating in, 219
Indinavir, adherence to triple antiretroviral treatment, 253
Injecting drug users (IDUs), HIV risk reduction in, in Thailand, 88
Injection drug use
frequency, and needle exchange, clinical trial, 199
in HIV-positive and HIV-negative women, 500
impact of HCV coinfection on HIV progression before and after HAART, 365
and noninjection, in northern Thailand, HIV-1 prevalence and risks among, 259
Insulin resistance, in HIV-infected subjects: comparison of PI-treated and non-PI-treated groups, 34
Insulin secretion, in HIV-infected subjects: comparing PI-treated and non-PI-treated, 34

Integration, of HIV within host cell genes in HIV DNA tissues and macrophage-associated p24 antigen expression, 308
Internet, high-risk practice among older adults, S226
Intervention(s)
assessing effectiveness in other settings: rationale 1(letter), 276
targeting older minority MSM, S222
Iron, haptoglobin phenotype, and HIV-1 viral load: cross-sectional study among pregnant women, 74

Jamaica, seroincidence of HTLV-1 infection and seroconverters in food handlers from, 387

Kaposi's sarcoma
epitope mapping in inactivated tat-vaccinated healthy and HIV-1-infected volunteers, 47
in Uganda and risk factors for HHV-8 infection among blood donors, 206

Late-stage HIV-1 infection, on in vitro and in vivo maturation of myeloid dendritic cells, 413
LCx, and HIV-1 divergent strains, 1
Leptin replacement therapy, not dietary polyunsaturated fatty acid alleviates HIV PI-induced dyslipidemia and lipodystrophy, 564
Less-sensitive EIA, for detection of early HIV-1 infection, development of, 349
Letters to editor
Antiretroviral treatment and advanced age, 112
Bone mass in HIV-infected patients: focus on role of therapy and sex, 405
CD4 cell count among HIV-infected patients with AIDS-defining disease, 279
Delayed-type hypersensitivity skin testing can predict CD4 count increase, 277
Efavirenz-based regimen as treatment of advanced AIDS, 118
HIV infection, high prevalence of, among women and their children in Henan Province, China, 649
Immigrants, HIV-infected, from non-European union countries and antiretroviral treatment, 408
Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients, 655
Lipid abnormalities, evolution of, in patients switched from stavudine- to tenofovir-containing regimens, 544
Liver toxicity, incidence of, in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy, 546
Metabolic profile, changes in, among antiretroviral-naive patients initiating protease inhibitor *vs.* non-protease inhibitor containing HAART regimens, 653
Methadone dose alterations, lack of, or withdrawal symptoms during therapy, 650
Phase 3 preventive HIV-1 vaccine trial, response to willingness to participate and enroll in, 412
Pilot study of directly observed therapy in highly nonadherent HIV-infected patients in urban community-based institution, 651
Protease inhibitors, effect of on apolipoprotein B levels and plasma lipid profile, 114
Rationale 1: to assess intervention's likely effectiveness in other settings, 276
Rationale 2: to assess whether cross-site variations in usual care explain cross-site variations in effectiveness, 276
Rationale 3: to contamination of usual care control, 276
Screening, systematic, of cryptococcal antigenemia in HIV-positive adults in Uganda, 411
Screening for substance use, sexual practices, mental illness, and domestic violence in HIV primary care, 548
Screening subtle HIV-related cognitive dysfunction, 116
Sustained HIV-1 suppression in treatment-naive patients undergoing 4- to 3-drug induction maintenance therapy, 543
Uncontrolled herpes simplex virus-2 as cofactor in HIV transmission, 119
Usual care, assessing in clinical trials of adherence interventions, 276
Voluntary counseling and testing center, usefulness of for HIV/AIDS, 407
LightCycler, technology RNA quantification and HIV-1 divergency based on, 1
Lipid abnormalities, in patients switched from stavudine- to tenofovir-containing regimens (letter), 544
Lipids, in HIV-infected subjects with lipoatrophy, antioxidants on glucose metabolism and, 605
Lipoatrophy
effect of antioxidants on glucose metabolism and plasma lipids in HIV-infected subjects with, 605
switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse, 29
Lipodystrophy
and dysplipidemia comparison of Abacavir-based replacements in management, 22
effects of antioxidants on glucose metabolism and plasma lipids in HIV-infected subjects with lipoatrophy, 605
severity grading scale from lipodystrophy case definition score, 571
Lipoproteins, leptin replacement therapy not dietary polyunsaturated fatty acid and HIV PI-induced dyslipidemia and lipodystrphy, 564
Liver biopsy alternatives, correlation of SPECT as, in assessing liver involvement in HIV and HCV coinfection, 329
Liver steatosis, leptin replacement therapy not PUFA and HIV PI-induced dyslipidemia and lipodystrophy, 564
Liver toxicity, in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy (letter), 546
Longitudinal study(-ies)
$CD4^+$ T lymphocyte count and HIV RNA as markers in naive HIV patient treated with HAART, 380
drug use patterns over time in HIV-positive and HIV-negative women, 500
HIV impact on mother and child mortality in rural Tanzania, 393
stability of adherence to HAART in treatment adherence demonstration project, 484

Lopinavir, and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience, HIV-1 phenotypic susceptibility to, 439
Lopinavir plasma levels, and changes in lipid levels during salvage therapy with LPV/r-containing regimens, 594
Low income, senior housing complexes, factors affecting exposure to HIV/AIDS risk among older residents living in, S138
LTR, globin haplotypes of HTLV-1- infected persons in Salvador, Bahia, Brazil, suggest post-Columbian African origin of virus, 536
Lymphocytes, mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers, 175

Male safety, and acceptibility of penile application of topical microbicides, 476
Marriage, and HIV risk in areas with high prevalence of HIV infection, 526
Mature women, and risk factors and HIV transmission, S122
Men, HIV epidemic and MSM, S115
Mental health, combination antiretroviral therapy and improvements in: results in US, 104
Men who have sex with men
  older, and HIV epidemic, S115
  triple jeopardy: targeting older men of color, S222
  unprotected anal intercourse between persons of different HIV serostatus in San Francisco, 157
MESH headings, economic implications of failure to reduce HIV infections by 50% by 2005 in US, 171
Metabolic complications, in HIV-infected subjects: comparing PI-treated and non-PI-treated, 34
Metabolic profile, among antiretroviral-naive patients initiating PI *vs.* non-PI with HAART regimens (letter), 653
Metabolism, glucose, and plasma lipids in HIV-infected subjects with lipoatrophy, effects of antioxidants on, 605
Methadone, lack of dose alterations or withdrawal symptoms during therapy with LPV/r (letter), 650
Methamphetamines, and HIV prevalence and risks among injection and noninjection drug users in northern Thailand, 259
Methods, and conceptual issues in research on age and aging, S206
MIcrobicide, safety and acceptability of penile application, 476
Middle-aged and older adults, designing effective HIV/AIDS social and behavioral interventions for, S194
Minority, older populations and HIV research, S218
Minority MSM, targeting, S222
Mitochondrial DNA, toxicity, in HIV-uninfected infants born to HIV-infected mothers, 175
Mitochondrial toxicity, blood lymphocyte mtDNA for monitoring of antiretroviral drug-induced mtDNA depletion, 461
Mode of delivery, increasing trends of cesarean deliveries in HIV-infected women in U.S. from 1994–2000, 232
Mother's survival, HIV impact on, and child mortality in rural Tanzania, 393
Mucosal transmission, simian human immunodeficiency virus encoding envelope gene from CCR5-tropic HIV-1 Ba-L, 300
Mutation
  HIV-1 genotypic patterns responsible for interalgorithm discordances, 8
  HIV integration within host cell genomic DNA and macrophage-associated p24 antigen expression, 308
  NRTI- associated, and Tenofovir in treatment-experienced HIV-1-infected patients, 15
Myocobacterium avium, complex infection and HLA class II in HIV-1-serpositive whites, 140

Natural history, clinical and immunologic progression in HIV-infected US women before and after HAART introduction, 614
Natural killer receptors, on Vδ1 γδ T cells in HIV-1-infected patients, 420
Needle exchange, and injection drug use frequency, clinical trial, 199
Neuropsychology, and younger and older HIV-1-infected adults, S93
Nevirapine
  effects of prednisone on rash associated with, 41
  predose infant, with two-dose intrapartum neonatal nevirapine regimen, 153
New injectors, HIV and HCV risk in, in Oslo, Norway, 373
Nonnucleoside reverse transcriptase inhibitor
  protease inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells, 551
Nucleoside reverse transcriptase inhibitor(s)
  blood lymphocyte mtDNA for monitoring antiretroviral drug-induced mtDNA depletion, 461
  and HIV-1-infected persons, intermittent use of high-dose stavudine to, 343
  and mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers, 175

Older adults
  and factors affecting exposure to HIV/AIDS risk among, living in low-income senior housing complexes, S138
  finding sex partners on-line: new high-risk practice among, S226
  with HIV: one woman's story, S166
  and HIV infection, S169
  travel, tourism, and HIV risk among, S233
Older individuals, differences in symptom expression in HIV-positive, S84
Older MSM, targeting, S222
Older persons
  and AIDS: international perspective, S153
  and AIDS at end of twentieth century, S68
On-line sex, high-risk practice among older adults, S226
Opportunistic illness, and survival, trends, influence on: AIDS wasting syndrome, 267
Osteopenia, as risk factor for HIV infection (review article), 281
Osteoporosis, as risk factor for HIV infection (review article), 281

p24 antigen, as HIV-1 inverse correlate of CD4 T-cell change under long-term antiretroviral therapy, 292

Parental caregiving, AIDS and older persons: international perspective, S153
Patient adherence, survival in HIV-1 clinic in era of HAART: 5-year study, 321
Pediatric, infected and uninfected, born to HIV-infected women, age-related cellular immunity patterns in, 635
Perinatal HIV transmission, in U.S. from 1994–2000, increasing trends of cesarean deliveries, 232
Peripheral blood mononuclear cells, protease inhibitors and NNRTIs on P-glycoprotein expression in, 551
P-glycoprotein expression in peripheral blood mononuclear cells, effects of protease inhibitors and NNRTIs on, 551
Pharmacodynamics, intermittent use of high-dose stavudine to nucleoside-experienced HIV-1-infected persons, 343
Pharmacy, assessment of contribution of determination of concentration of indinavir, role of determination of plasma levels of indinavir, 253
Phase 3 preventive HIV-1 vaccine trial, willingness to participate and enroll in (letter), 412
Phenotype, HIV-1, susceptibility to LPV and genotypic analysis in LPV/r-naive subjects with prior PI experience, 439
Placental transfer, predose infant nevirapine with two-dose intrapartum neonatal nevirapine regimen and, 153
Plasma levels, of indinavir, adherence to triple antiretroviral treatment including indinavir, 253
Positive influence, distress, and well-being in older men with HIV-infection, S185
Potent antiretroviral therapy, and prevalence of unsafe sexual behavior among HIV-infected individuals, 494
Prednisone, effects on rash associated with nevirapine in HIV-1 patients, 41
Pregnancy
  iron, haptoglobin phenotype, HIV-1 viral load, and, 74
  predose infant nevirapine with two-dose intrapartum neonatal nevirapine regimen, 153
  progression of HIV in women after delivery, 585
Prevention
  of HIV/AIDS and care services for aging: bridging gap between service systems to assist older people, S243
  safety and acceptability of penile application of topical microbicides, 476
Primary prevention, and economics of failure to reduce HIV by 50% by 2005 in U.S., 171
Primary resistance, mutations at residue positions critical for, in patients with subtype B and non-B HIV-1, 134
Primate model, from CCR5-tropic HIV-1 Ba-L, simian human immunodeficiency virus encoding, 300
Probability sample, of MSM and HIV infection with associated risks in Florida resort community, 223
Proficiency testing, of new less sensitive HIV-1 enzyme immunoassay, 625
PRO 2000 Gel, safety and acceptability of penile application, 476
Prognosis, $CD4^+$ T lymphocyte count and HIV RNA as markers in naive HIV-1-infected patients treated with HAART, 380
Progression, impact of HCV coinfection on HIV, before and after HAART, 365
Protease, HIV-1, and reverse transcriptase mutation patterns, discordances between genotypic drug resistance interpretation algorithms, 8
Protease inhibitor(s)
  combination antiretroviral treatment and improvements in mental health: results in US, 104
  effects on apolipoptotein B levels and plasma lipid profile in HIV-1 subjects on highly active antiretroviral therapy (letter), 114
  HAART and HCV infection on development of hyperglycemia in HIV-infected persons, 577
  LPV plasma concentrations and changes in lipid levels during salvage therapy with, 594
  and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells, 551
  quantification of insulin-mediated glucose disposal, comparing patients treated and untreated with, 34
  reviving: new data and more options, S43
  -sparing regimens: new evidence strengthens position, S17
Proto-oncogene, HIV integration within host cell genomic DNA and macrophage-associated p24 antigen expression, 308
Provirus load, seroincidence of HTLV-1 infection and characterization of seroconverters in Jamaican food handlers, 387
Puberty, delayed development of in children and adolescents with perinatally acquired HIV infection, 56

Quality assurance, performance of new LS HIV-1 EIAs in estimating HIV seroincidence, 625
Quality control, performance of new LS HIV-1 EIAs in estimating HIV seroincidence, 625
Quality of life, among diverse older HIV-positive population, S76
Questionnaires, for assessing adherence to triple antiretroviral treatment including indinavir, 253

Race, and gender differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women, 635
Rapid HIV testing, and antibody performance and acceptability among women in northern Thailand, 194
Rash, effects of prednisone on, with nevirapine in HIV-1-infected patients, 41
Research ethics, of community consultation in HIV prevention, 513
Reverse transcriptase, and HIV-1 protease mutation patterns, discordances between genotypic drug resistance interpretation algorithms, 8
Risk factors, of HIV to marriage among areas of high prevalence of HIV infection, 526
Ritonavir, leptin replacement therapy not PUFA diet alleviates HIV PI-induced dyslipidemia and lipodystrophy, 564
RNA level, hepatitis C prevalence, activity, and genotype with HIV in cohort in New York City drug users, 356
RNA quantification, and HIV-1 divergent strains, 1

Safer sex, risk factors and HIV transmission to mature women, S122
Salvador-Brazil, globin haplotypes of HTLV-1-infected persons in, suggest post-Columbian African origin of virus, 536
Screening, for substance use, sexual practices, mental illness, and domestic violence in HIV primary care (letter), 548
Senior HIV Intervention Project, reaching retirement communities and aging social networks in south Florida, S238
Senior housing, factors affecting exposure to HIV/AIDs risk among older residents in, S138
Seniors
  in south Florida, strategies for reaching retirement communities and aging social networks: HIV/AIDS prevention activities among, S238
Seroconverters, HIV, and impact of TB on HIV progression in persons with well-documented time of, 184
Seroincidence, of human T-lymphotropic virus type 1 infection and characterization of seroconverters in Jamaican food handlers, 387
Service delivery, HIV/AIDS prevention and care services for aging, S243
Severe hepatotoxicity, associated with subsequent antiretroviral therapy in pretreated HCV patients with HIV and hepatitis C virus reduces, 146
Severity, grading scale from lipodystrophy case definition score, 571
Sexual behavior
  of MSM in Florida resort community and HIV infection and associated risks, 223
  unsafe, among HIV-infected individuals, 494
Sexually transmitted diseases
  in HIV-infected patients, makers for ongoing HIV transmission behavior, 247
  value of screening for, in HIV clinic, 642
Sexual partners, unprotected sex among MSM of different HIV serostatus in San Francisco, 157
Sexual risk behavior, of MSM and Viagra use in San Francisco, 191
SHIV, encoding envelope gene from CCR5-tropic HIV-1 Ba-L, 300
Single photon emission computer tomograph, parameters as alternative to liver biopsies in assessing liver involvement in HIV and HCV, 329
Social and behavioral intervention, in HIV/AIDS prevention in mature men, S194
Social networks, factors affecting exposure to HIV/AIDS risk among older residents in low-income senior housing complexes, S138
Social support
  distress, and well-being in older men living with HIV infection, S185
  national profile of economic circumstances, and quality of life and diverse older HIV-positive population, S76
Socioeconomic status, and association with death rate in era of HAART, San Francisco, 96
Southern Africa, globin haplotypes of HTLV-1-infected persons in, suggest post-Columbian African origin of virus, 536
Stavudine, intermittent administration of high-dose, to nucleoside-experienced HIV-1-infected persons, 343
Structured treatment interruption, of high-dose stavudine to nucleoside-experienced persons infected with HIV-1, 343
Substance abuse, and HIV risk reduction in Thailand, 88
Substitution
  in abacavir-based approaches in managing dyslipidemia and lipoatrophy, 22
  and CAM use for conventional therapy by HIV patients, 157
Subtypes, B and non-B HIB-1 strains, mutations at residue positions critical for enfuvirtide (T-20) resistance in patients with, 134
Survival
  impact of HCV coinfection on HIV progression before and after HAART, 365
  lower rate of, in era of highly active antiretroviral therapy, low socioeconomic status and, 96
Switching study, with stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy, 29
Symptoms, differences in expression in older HIV-positive patients, S84
Syringe exchange program, HIV and HCV risk in new and longer-term injecting drug users in Oslo, Norway, 373

Tat, identification of immunodominant epitopes in inactivated, and HIV-1 volunteers, 47
Telomere, and mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers, 175
Tenofovir, in treatment-experienced HIV-1-infected patients, 15
Thailand
  AIDS and older persons, S153
  HIV prevalence and risks among injection and noninjection drug users in, 259
  northern, rapid HIV testing for HIV antibody among women of, 194
Time-dependent model, serum albumin is predictor of survival of HIV-1-infected women, 66
T lymphocytes, incomplete recovery in HIV-1 infection after HAART associated with CD4 T cell activation and turnover, 125
Tourism, travel and HIV risk among older adults, S233
Transmission, of HHV-8 infection among blood donors linked to Kaposi's sarcoma in Uganda, 206
Travel, tourism, and HIV risk among older adults, S233
Tuberculosis, impact on HIV progression in persons with well-documented time of HIV seroconversion, 184

Vaccine, tat-toxoid, and HIV-1-infected volunteers, identifying epitopes in inactivated, 47
Vertically acquired infection, of children and gender and race differences in cellular immunity patterns over age in, 635
Viagra, in community-recruited sample of MSM, San Francisco, 191
Viral dynamics, baseline factors and virologic responses in treatment-naive HIV-1-infected patients, 557

Viral fitness, role of baseline *pol* genotype in HIV-1, 448
Viral load
  $CD4^+$ T lymphocyte count and HIV RNA as markers in naive HIV-1-infected patients treated with HAART, 380
  and cognitive functioning in younger and older HIV-1-infected adults, S93
  and hepatitis C prevalence, activity, and genotype with HIV infection in cohort in New York City drug users, 356
  and HIV-1 divergent strains, 1
  HIV-1 p24 antigen as inverse correlate of CD4 T-cell change under long-term antiretroviral therapy, 292
Voluntary counseling, usefulness of, and testing center for HIV/AIDS (letter), 407
Voluntary counseling and testing, feasibility, demand, and effect of integrating primary care services, 470

Wasting syndrome, AIDS: trends, influence on opportunistic infections, and survival, 267
Whole-blood specimen, for rapid HIV testing of antibody performance and acceptability among northern Thailand women, 194
Women
  clinical and immunologic progression in HIV-infected US, before and after HAART introduction, 614
  drug use patterns in HIV-positve and HIV-negative, 500
  HIV-infected and uninfected postpartum in US, contraception, family planning, and unprotected sex among, 608
Women and infants transmission study, mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers, 175
Women with HIV, and aging: one woman's story, S166

Zidovudine, intermittent use of high-dose stavudine to nucleoside-experienced HIV-1-infected persons, 343
Zimbabwe, study on pregnancy, iron, haptoglobin phenotype, and HIV-1 viral load, 74